Starfighters Space Borrow Rate Increases to 282.66%

Written by Emily J. Thompson, Senior Investment Analyst

ABVX-6.57%

FJET-2.8%

GILD-2.26%

Updated: 3d ago

0mins

Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 282.66% +4.55, PureCycle Technologies (PCT) 7.61% +1.46, Infosys (INFY) 10.84% +1.06, Defiance 1.75x MSTR ETF (MSTX) 25.48% +0.42, Guggenheim Global Solar Index (TAN) 10.29% +0.37, - Abivax SA American Depositary Shares (ABVX) 0.66% +0.20, Direxion Daily Regional Banks Bull 3X Shares (DPST) 1.05% +0.18, Gilead (GILD) 0.42% +0.17, iShares DJ US Home Construction Index Fund (ITB) 2.71% +0.16, and Novo Nordisk (NVO) 0.41% +0.16.

ABVX

$116.8+Infinity%1D

Analyst Views on ABVX

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 125.010

Low

101.00

Averages

129.25

High

176.00

Current: 125.010

Low

101.00

Averages

129.25

High

176.00

Morgan Stanley

Overweight

maintain

$101 -> $145

Al Analysis

2026-01-09

Reason

Morgan Stanley

Price Target

$101 -> $145

Al Analysis

2026-01-09

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Abivax to $145 from $101 and keeps an Overweight rating on the shares after the company provided its 2026 corporate outlook highlighting new market research and clinical progress ahead of next week's investment conference in San Francisco. As the firm has continued to interrogate the market opportunity for obefazimod in UC, it has found that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program, the analyst added.

BTIG

Julian Harrison

Buy

maintain

$120 -> $150

2026-01-08

Reason

BTIG

Julian Harrison

Price Target

$120 -> $150

2026-01-08

maintain

Buy

Reason

BTIG analyst Julian Harrison raised the firm's price target on Abivax to $150 from $120 and keeps a Buy rating on the shares. Abivax provided an updated 2026 pipeline outlook highlighting strong Phase 3 ABTECT induction data for obefazimod, positioning it as a preferred, flexible oral option across the moderate-to-severe treatment paradigm, with no new safety signals reported to date, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

Guggenheim

Yatin Suneja

Buy

maintain

$150 -> $175

2025-12-18

Reason

Guggenheim

Yatin Suneja

Price Target

$150 -> $175

2025-12-18

maintain

Buy

Reason

Guggenheim analyst Yatin Suneja raised the firm's price target on Abivax to $175 from $150 and keeps a Buy rating on the shares based on the firm's "optimistic outlook" for obefazimod in the 44-week maintenance readout that is upcoming.

Piper Sandler

NULL -> Overweight

maintain

$112 -> $142

2025-12-16

Reason

Piper Sandler

Price Target

$112 -> $142

2025-12-16

maintain

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on Abivax to $142 from $112 and keeps an Overweight rating on the shares.

About ABVX

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.